Company news

CytomX Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CytomX Therapeutics Announces New Employment Inducement Grants

May 15, 2024

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

May 7, 2024

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

May 6, 2024

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

April 30, 2024

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

April 7, 2024

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

April 2, 2024

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

March 20, 2024

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

March 17, 2024

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

March 10, 2024

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

March 3, 2024

CytomX Therapeutics to Present at Upcoming March Investor Conferences

February 26, 2024

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

January 23, 2024

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

January 11, 2024

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

January 3, 2024

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 20, 2023

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023

CytomX Therapeutics to Present at Upcoming November Investor Conferences

October 31, 2023

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

October 30, 2023

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

October 29, 2023

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

October 17, 2023

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

August 9, 2023

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 7, 2023

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

July 31, 2023

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

July 16, 2023

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

June 29, 2023

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

April 30, 2023

CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

April 24, 2023

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

March 26, 2023

CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

March 21, 2023

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

January 25, 2023

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference

January 16, 2023

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

January 4, 2023

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 4, 2023

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

December 21, 2022

CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 19, 2022

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

December 6, 2022

Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

November 16, 2022

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

November 16, 2022

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

November 7, 2022

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

November 6, 2022

CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022

October 31, 2022

CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249

September 11, 2022

CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051

September 6, 2022

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 3, 2022

CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences

August 2, 2022

CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

July 27, 2022

CytomX Therapeutics Provides Strategic Update

July 12, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 29 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.